PREV - WoW.. All this and more to come... $$$$$ PREVECEUTICAL PROVIDES YEAR END CORPORATE UPDATE
Preveceutical Medical Inc. has provided an update on the company's progress in its continuing corporate initiatives.
Preveceutical has achieved several notable milestones this year and continues to execute its strategy to become a global preventive health care company. These milestones include: signing a letter of intent with Crushedit LLC in respect of a $16.25-million cannabidiol (CBD) isolate supply agreement; entering into a natural health product licensing agreement with Asterion Cannabis Inc.; launching a medicinal cannabis division; completing a $6.5-million financing; and expanding its Australian operations.
The company has reached its 2018 research targets for its scorpion venom-derived peptide program and the soluble-gel (sol-gel) drug delivery platform program and completed a workshop in Australia to advance its dual-gene therapy research and development program.
Letters of intent
In November, the company announced that it had entered into a letter of intent with Crushedit, whereby Preveceutical's cannabis division would supply Crushedit with a minimum of 2,500 kilograms of CBD isolate over a 12-month period at a purchase price of $6,500 per kilogram for aggregate proceeds of at least $16.25-million.
The company also announces that its letter of intent with the Penta 5 Group (see news release dated Oct. 3, 2018) has expired. During its due diligence of the Penta 5 Group, the company became aware of unexpected complexities regarding the structure of the group that made the proposed share purchase transaction unfeasible. The company and the Penta 5 Group are in negotiations regarding possible alternative transaction structures involving the purchase or joint ventures of individual products. The company continues to seek other revenue streams.
Licensing agreement with Asterion
On Aug. 14, 2018, Asterion granted Preveceutical a worldwide licence to use, manufacture, distribute and sell three Health Canada-approved natural health products. The natural health products consist of three natural sleep aids: Blissful Sleep, Blissful Sleep Ex and Skullcap Serenity. The ingredients in these natural health products have traditionally been used in herbal medicine to aid sleep and relieve anxiety and pain. All of the natural health products have undergone thorough testing and meet or exceed the requirements of the European Pharmacopoeia and Health Canada. The company plans to begin manufacturing the natural health products and selling them in retail pharmacies, health-conscious stores as well as on the company's website.
Cannabis division
The cannabis division is responsible for bringing medicinal cannabis-based products developed by the company to market and overseeing the company's sol-gel program and its resultant formulations. Through the sale of the medicinal cannabis products, the company aims to help consumers address a number of ailments, including chronic pain, epilepsy, anxiety disorders and more. Moving forward, the cannabis division will seek out additional cannabis products and technologies for the company to commercialize, ranging from transdermal patches and topical creams to capsules and novel methods of administering the medicinal cannabis.
Financing
On June 29, 2018, the company closed a non-brokered private placement of 130,799,750 units at a price of five cents per unit for gross proceeds of $6,539,988. The proceeds will be used to finance the company's research and development programs and for general working capital purposes.
Australian operations
Expanded operations and Aurora Cannabis Inc. shipments
The company expanded its operations and incorporated an Australian subsidiary, Preveceutical (Australia) Pty Ltd. The decision to expand its Australian operations was influenced by Australia's strong foundation of academic and clinical research as well as the Australian research and development tax incentives.
The company conducts its research and development programs in Australia, and, after successfully applying for and receiving the necessary permits, Preveceutical arranged for two deliveries of medicinal cannabis from Canada by Aurora to the Pharmacy Australia Centre of Excellence at the University of Queensland for use in the sol-gel program.
The sol-gel program
By applying the sol-gel technology to cannabis, the company intends to develop therapies for relief from a range of symptoms, including pain, inflammation, anxiety, seizures and neurological disorders. The advantages of sol-gels over conventional liquid nasal sprays include: longer therapeutic effects, reduced dosage requirements and reduced negative side effects (such as irritation).
This year, the sol-gel program included the preparation of sol-gel formulations containing fixed cannabidiol/tetrahydrocannabinol concentrations, which, when sprayed using the company's custom applicator, will be able to safely and consistently deliver cannabidiol/tetrahydrocannabinol to the central nervous system in predefined ratios. This will enable the development of medicinal cannabis products tailored for a broad range of ailments and diseases, optimizing the conditions for extracting cannabinoids from the five cannabis strains provided by the company's licensed producer (LP) partner, Aurora, and developing the company's custom sol-gel applicator.
In September and November, the company optimized a proprietary extraction protocol, developed an optimized protocol to convert phytocannabinoids from all five of the company's cannabis strains from their acid to neutral forms, and announced encouraging results from its sol-gel applicator trials for achieving direct nose-to-brain delivery in an adult human nasal cast.
Traditional liquid nasal sprays are not retained in the nasal cavity for any appreciable time and are only capable of generating random spray and deposition. In contrast, the company's sol-gel applicator generates a precise spray profile that directs the sol-gel formulation high into the upper nasal cavity, where it remains following rapid gelation. This is an important development as the region targeted by the sol-gel is adjacent to the olfactory epithelium, which serves as a direct passage for molecules into the brain.
Dual-gene therapy research program
In October, Preveceutical's research team at the University of Queensland, held a two-day intensive workshop, which brought together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth to collaborate on Preveceutical's dual-gene therapy program, which is intended to address the increasing prevalence of obesity and diabetes using smart siRNA and tissue-targeted bio-responsive delivery systems.
The primary objectives of the workshop were to share key data derived to date from gene engineering, delivery system design and synthesis, and their evaluation in cellular models of diabetes and obesity. The teams assessed and resolved potential assay bottlenecks, paving the way for high-throughput screening of smart siRNA candidate libraries, which is anticipated to expedite the program's progress.
During the workshop, the teams created a 10-to-12-month plan aimed at successfully concluding the current phase of the dual-gene therapy program by demonstrating proof of concept in the delivery of smart siRNAs and effective in-cell modulation of a key biomarker implicated in diabetes and obesity.
Once the current phase of the dual-gene therapy program is complete, it will move to the final phase where the safety and efficacy of the primary smart siRNA-delivery system constructs will be evaluated in preclinical models of diabetes and obesity.
The peptide program
Phase 1 of the peptide program yielded promising results as Preveceutical's research team identified eight peptide candidates for the company's future Nature Identical peptide therapeutics, which are intended to treat, regulate and prevent cancer progression.
Phase 2 of the peptide program is now under way as the company works to redesign the peptides, with the goal of enhancing their biostability, while maintaining their potency during screening against well-characterized and defined targets associated with brain cancer. In phase 3, the company will begin to screen the peptides in cell-based cancer models.
About Preveceutical Medical Inc.
Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
Preveceutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual-gene therapy for curative and prevention therapies for Type 2 diabetes and obesity; a sol-gel drug delivery program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
We seek Safe Harbor.